cellvie AG

cellvie is bringing about a new treatment modality, leveraging the therapeutic potential of mitochondria. Specifically, it was shown that mitochondria, the powerhouses of the cell, can be augmented and replaced in compromised cells. The approach was developed at Harvard, but taken to Switzerland by its founders in conjunction with the first funding round. Safety and efficacy was established in >20 pre-clinical studies and an ongoing clinical pilot at Boston Children's Hospital. The technology's initial application will be in ischemia-reperfusion injury, with kidney transplantation as first indication, for which FDA Orphan Drug Designation was obtained.